Browse Articles

Discover research articles across all indexed journals

Covered Stent Correction for Sinus Venosus Atrial Septal Defects, an Emerging Alternative to Surgical Repair: Results of an International Registry

Circulation Eric Rosenthal, Shakeel A. Qureshi, Kothandam Sivakumar et al. Mar 18, 2025 DOI: 10.1161/circulationaha.124.070271

BACKGROUND: Covered stent correction for a sinus venosus atrial septal defect (SVASD) was first performed in 2009. This innovative approach was initially viewed as experimental and was reserved for highly selected patients with unusual anatomic variants. In 2016, increasing numbers of procedures began to be performed, and in several centers, it is now offered as a standard of care option alongside surgical repair. However, covered stent correction for SVASD is not recognized by regulatory authorities, and in the minds of many pediatric and adult congenital cardiologists and surgeons, the condition is viewed as treatable only by cardiac surgery with cardiopulmonary bypass. METHODS: In April 2023, all centers identified from international conferences, publications, and colleague networks to be undertaking covered stent correction for SVASD were invited to participate in a retrospective audit of their procedures. RESULTS: Data were received on 381 patients from 54 units over a 12-year period with 90% of procedures being performed over the past 5 years. Balloon-expandable stents (8 types) were used in the majority; self-expanding stents (4 types) were used in 4.5%. The commonest stent was the 10-zig covered Cheatham Platinum stent in 62% of cases. In 10 procedures, the stent embolized requiring surgical retrieval and repair of the defect, resulting in technically successful implantation in 371 of 381 (97.4%). Major complications (surgical drainage of tamponade, pacemaker implantation, surgery for pulmonary vein occlusion, and late stent removal) occurred in 5 patients (1.3%). Repeat catheterization to correct residual leaks was required in 7 patients (1.8%). Thus, 359 of 381 patients (94.2%) had successful correction without major complications or additional catheter interventions. CONCLUSIONS: This article details the exponential uptake of covered stent correction for SVASD during the past 5 years. Cardiopulmonary bypass was avoided in the majority of patients, and major complications were infrequent. Prospective registries with standardized definitions, inclusion criteria, and follow-up and comparative studies with surgery are now required to help support the extension of covered stent correction as an alternative standard-of-care option for patients with an SVASD.

Identification of methionine metabolism related prognostic model and tumor suppressive functions of BHMT in hepatocellular carcinoma

Scientific Reports Wenli Liu, Kaiheng Hu, Yaqing Fu et al. Mar 18, 2025 DOI: 10.1038/s41598-025-93650-w

Correction to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy

Circulation Joshua K. Meisner, Aaron Renberg, Eric D. Smith et al. Mar 18, 2025 DOI: 10.1161/cir.0000000000001318

Development of CoAP protocol for communication in mobile robotic systems using IoT technique

Scientific Reports Chandra Sarkar, Amitava Das, Ravi Kant Jain Mar 18, 2025 DOI: 10.1038/s41598-024-76713-2

A Young Man With Syncope: What Is the Diagnosis?

Circulation Pongprueth Rujirachun, Svita Taveeamornrat, Arjbordin Winijkul Mar 18, 2025 DOI: 10.1161/circulationaha.124.072433

Utility of global longitudinal strain in early identification of chronic cardiotoxicity in asymptomatic long-term malignant lymphoma survivors with normal left ventricle ejection fraction

Scientific Reports Eva Rihackova, Michal Rihacek, Lubos Boucek et al. Mar 18, 2025 DOI: 10.1038/s41598-025-93933-2

Abstract Malignant lymphoma survivors are at increased risk for anthracycline and/or radiotherapy-induced chronic cardiotoxicity. Proper long-term follow-up is essential for malignant lymphoma survivors after-care. This study aimed to assess TTE parameters of potential subclinical cardiotoxicity and to examine their utility in diagnosing chronic cardiotoxicity. Improvement of the diagnostic process may precede the manifestation of cardiac adverse events. Main objective of the study was to improve the identification of cancer survivors in increased risk of treatment cardiotoxicity. To achieve this goal, utility of various echocardiography parameters was examined.In this retrospective study we analysed TTE of 167 subjects with speckle tracking according to the European Society of Echocardiography guidelines during the follow-up period. 88 of them were long-term lymphoma survivors diagnosed with malignant lymphoma between the years 1994–2015. Minimum follow up period was 5 years with the median of 10 years after anti-cancer treatment cessation. TTE were performed between the years 2017–2022 at cardio-oncology outpatient office during regular follow-up period. A total of 79 volunteers with no history of chronic heart failure (CHF) or decline in LVEF, 51 (64.6%) of whom were males, with the median age of 46 (16–58) years were included in the analysis as control group. Control subjects had various indications for TTE (e.g. preoperative examination, benign palpitations, or with well controlled arterial hypertension taking two antihypertensives at most). Ischemic heart disease was ruled out by stress test. None of the control subjects had history of stroke or chronic lower limb ischemia. All control subjects were considered clinically stable with no sign of cardiac impairment caused by primary disease. Both cancer survivors and control group were divided into subgroups based on LVEF: lower normal LVEF (53–61%), and higher normal LVEF (> 61%). Survivors with lower normal LVEF (53–61%) had a statistically significant decline in GLS compared to those with higher normal LVEF (> 61%). This phenomenon was not observed in control group indicating a possible additional diagnostic value of this parameter. Inclusion of GLS assessment in follow-up TTE examination of subjects with lower normal LVEF may improve the sensitivity of detection of chronic cardiotoxicity. Patients with declined GLS and lower normal LVEF are candidates for intensified follow-up to precede manifestation of cardiac adverse events.

The Mysterious Masks of Hypercholesterolemia: A Unique Clinical Case

Circulation Uliana Chubykina, Petr Vasiluev, Olga Ivanova et al. Mar 18, 2025 DOI: 10.1161/circulationaha.124.071638

Vibration signal analysis for rolling bearings faults diagnosis based on deep-shallow features fusion

Scientific Reports Ahmed Chennana, Ahmed Chaouki Megherbi, Noureddine Bessous et al. Mar 18, 2025 DOI: 10.1038/s41598-025-93133-y

Abstract In engineering applications, the bearing faults diagnosis is essential for maintaining reliability and extending the lifespan of rotating machinery, thereby preventing unexpected industrial production downtime. Prompt fault diagnosis using vibration signals is vital to ensure seamless operation of industrial system avert catastrophic breakdowns, reduce maintenance costs, and ensure continuous productivity. As industries evolve and machines operate under diverse conditions, traditional fault detection methods often fall short. In spite of significant research in recent years, there remains a pressing need for improve existing methods of fault diagnosis. To fill this research gap, this research work aims to propose an efficient and robust system for diagnosing bearing faults, using deep and Shallow features. Through the evaluated experiments, our proposed model Multi-Block Histograms of Local Phase Quantization (MBH-LPQ) showed excellent performance in classification accuracy, and the audio-trained VGGish model showed the best performance in all tasks. Contributions of this work include: Combine the proposed Shallow descriptor, derived from a novel hand-crafted discriminative features MBH-LPQ, with deep features obtained from VGGish pre-trained of Convolutional Neural Network (CNN) using audio spectrograms, by merging at the score level using Weighted Sum (WS). This approach is designed to take advantage of the complementary strengths of both feature models, thus enhancing overall bearing fault diagnostic performance. Furthermore, experiments conducted to verify the approach’s performance is assessed based on fault classification accuracy demonstrated a significant accuracy rate on two different noisy datasets, with an accuracy rate of 98.95% and 100% being reached on the CWRU and PU datasets benchmark, respectively.

Covered Stent Treatment for Sinus Venosus Atrial Septal Defects: Early Promise and Potential Limitations

Circulation Glen Van Arsdell, Doff B. McElhinney Mar 18, 2025 DOI: 10.1161/circulationaha.124.072394

Impacts of tourism on LULC and LST dynamics in district Buner and Shangla, Pakistan

Scientific Reports Waheed Ullah, Khalid Ahmad, Adnan Ahmad Tahir et al. Mar 18, 2025 DOI: 10.1038/s41598-025-94230-8

Response by Chan et al to Letters Regarding Article, “Race and Sex Differences in the Association of Bystander CPR for Cardiac Arrest”

Circulation Paul S. Chan, Saket Girotra, Monique A. Starks Mar 18, 2025 DOI: 10.1161/circulationaha.124.073360

Author Correction: A high-performance sub-THz planar antenna array for THz sensing and imaging applications

Scientific Reports Muhammad Zubair, Abdul Jabbar, Farooq A. Tahir et al. Mar 18, 2025 DOI: 10.1038/s41598-025-92482-y

The Role of Race in Cardiovascular Disease Risk Prediction

Circulation Chiadi E. Ndumele, Keith C. Ferdinand, Sadiya S. Khan Mar 18, 2025 DOI: 10.1161/circulationaha.124.071233

Study on the application and evaluation method of Zen aesthetic style in furniture design under the background of sustainability

Scientific Reports Tao Wang, Basyarah Hamat, Liming Zhang et al. Mar 18, 2025 DOI: 10.1038/s41598-025-93860-2

Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology

Circulation Jonathan H. Kim, Aaron L. Baggish, Benjamin D. Levine et al. Mar 18, 2025 DOI: 10.1161/cir.0000000000001297

Collaborators: Larry A. Allen, MD, MHS, FAHA, FACC; Mats Börjesson, MD, PhD, FACC; Alan C. Braverman, MD, FACC; Julie A. Brothers, MD; Silvia Castelletti, MD, MSc, FESC; Eugene H. Chung, MD, MPH, FHRS, FAHA, FACC; Timothy W. Churchill, MD, FACC; Guido Claessen, MD, PhD; Flavio D’Ascenzi, MD, PhD; Douglas Darden, MD; Peter N. Dean, MD, FACC; Neal W. Dickert, MD, PhD, FACC; Jonathan A. Drezner, MD; Katherine E. Economy, MD, MPH; Thijs M.H. Eijsvogels, PhD; Michael S. Emery, MD, MS, FACC; Susan P. Etheridge, MD, FHRS, FAHA, FACC; Sabiha Gati, BSc (Hons), MBBS, PhD, MRCP, FESC; Belinda Gray, BSc (Med), MBBS, PhD; Martin Halle, MD; Kimberly G. Harmon, MD; Jeffrey J. Hsu, MD, PhD, FAHA, FACC; Richard J. Kovacs, MD, FAHA, MACC; Sheela Krishnan, MD, FACC; Mark S. Link, MD, FHRS, FAHA, FACC; Martin Maron, MD; Silvana Molossi, MD, PhD, FACC; Antonio Pelliccia, MD; Jack C. Salerno, MD, FACC, FHRS; Ankit B. Shah, MD, MPH, FACC; Sanjay Sharma, BSc (Hons), MBChB, MRCP (UK), MD; Tamanna K. Singh, MD, FACC; Katie M. Stewart, NP, MS; Paul D. Thompson, MD, FAHA, FACC; Meagan M. Wasfy, MD, MPH, FACC; Matthias Wilhelm, MD This American Heart Association/American College of Cardiology scientific statement on clinical considerations for competitive sports participation for athletes with cardiovascular abnormalities or diseases is organized into 11 distinct sections focused on sports-specific topics or disease processes that are relevant when considering the potential risks of adverse cardiovascular events, including sudden cardiac arrest, during competitive sports participation. Task forces comprising international experts in sports cardiology and the respective topics covered were assigned to each section and prepared specific clinical considerations tables for practitioners to reference. Comprehensive literature review and an emphasis on shared decision-making were integral in the writing of all clinical considerations presented.

Design research on a smart infusion device to reduce medical workload and enhance patient safety

Scientific Reports Bo Mu, Yilun Wang, Xunchen Liu et al. Mar 18, 2025 DOI: 10.1038/s41598-025-93911-8

Letter by Tamirisa et al Regarding Article, “Race and Sex Differences in the Association of Bystander CPR for Cardiac Arrest”

Circulation Ketan Tamirisa, Ethan Lowder, Jim P. Stimpson Mar 18, 2025 DOI: 10.1161/circulationaha.124.071883

Characterization of rice starch changes in saline and alkaline area under different fertilization conditions based on Raman spectral recognition technology

Scientific Reports Zhipeng Li, Zhuang Miao, Changming Li et al. Mar 18, 2025 DOI: 10.1038/s41598-025-89102-0

Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy

Circulation Joshua K. Meisner, Aaron Renberg, Eric D. Smith et al. Mar 18, 2025 DOI: 10.1161/circulationaha.124.069398

BACKGROUND: Classically, hypertrophic cardiomyopathy (HCM) has been viewed as a single-gene (monogenic) disease caused by pathogenic variants in sarcomere genes. Pathogenic sarcomere variants are individually rare and convey high risk for developing HCM (highly penetrant). Recently, important polygenic contributions have also been characterized. Low penetrance sarcomere variants (LowSVs) at intermediate frequencies and effect sizes have not been systematically investigated. We hypothesize that LowSVs may be common in HCM with substantial influence on disease risk and severity. METHODS: Among all sarcomere variants observed in the Sarcomeric Human Cardiomyopathy Registry (SHaRe), we identified putative LowSVs defined by (1) population frequency greater than expected for highly penetrant (monogenic) HCM (allele frequency >5×10 -5 in the Genome Aggregation Database, gnomAD) and (2) moderate enrichment (>2×) in patients with HCM compared with gnomAD. LowSVs were examined for their association with disease severity and clinical outcomes. Functional effects of selected LowSVs were assessed using induced pluripotent stem cell–derived cardiomyocytes. Association of LowSVs with HCM-adjacent traits in the general population was tested using UK Biobank cardiac magnetic resonance imaging data. RESULTS: Among 6045 patients and 1159 unique variants in sarcomere genes, 12 LowSVs were identified. LowSVs were collectively common in the general population (1:350) and moderately enriched in HCM (aggregate odds ratio, 14.9 [95% CI, 12.5–17.9]). Isolated LowSVs were associated with an older age of HCM diagnosis and fewer adverse events. However, LowSVs in combination with a pathogenic sarcomere variant conferred higher morbidity (eg, composite adverse event hazard ratio, 5.4 [95% CI, 3.0–9.8] versus single pathogenic sarcomere variant, 2.0 [95% CI, 1.8–2.2]; P <0.001). An intermediate functional impact was validated for 2 specific LowSVs— MYBPC3 c.442G>A (partial splice gain) and TNNT2 c.832C>T (intermediate effect on contractile mechanics). Cardiac magnetic resonance imaging analysis of the general population revealed 5 of 12 LowSVs were significantly associated with HCM-adjacent traits without overt HCM. CONCLUSIONS: This study establishes a new class of low penetrance sarcomere variants that are relatively common in the population. When penetrant, isolated LowSVs cause mild HCM. In combination with pathogenic sarcomere variants, LowSVs markedly increase disease severity, supporting a clinically significant additive effect. Last, LowSVs also contribute to age-related remodeling even in the absence of overt HCM.

Micro-elimination initiative for hepatitis C screening: insight into gender gaps and undiagnosed individuals

Scientific Reports Annarita Valeria Piazzolla, Domenico Resta, Massimo Greco et al. Mar 18, 2025 DOI: 10.1038/s41598-025-91696-4